
Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.
Wood CEO Ken Gilmartin gives his insight on what's currently in demand in terms of new bio/pharma manufacturing facilities.
Ken Gilmartin, CEO, Wood, gives his insight on what's currently in demand in terms of new bio/pharma manufacturing facilities. He emphasizes that a significant amount of capital is being invested in the United States for facilities, particularly in the large molecule and cell and gene therapy sectors.
For more INTERPHEX 2023 video content, check






